These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 31472333)

  • 1. A review of Lassa fever vaccine candidates.
    Salami K; Gouglas D; Schmaljohn C; Saville M; Tornieporth N
    Curr Opin Virol; 2019 Aug; 37():105-111. PubMed ID: 31472333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene.
    Cai Y; Ye C; Cheng B; Nogales A; Iwasaki M; Yu S; Cooper K; Liu DX; Hart R; Adams R; Brady T; Postnikova EN; Kurtz J; St Claire M; Kuhn JH; de la Torre JC; Martínez-Sobrido L
    mBio; 2020 Feb; 11(1):. PubMed ID: 32098811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
    Safronetz D; Mire C; Rosenke K; Feldmann F; Haddock E; Geisbert T; Feldmann H
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003736. PubMed ID: 25884628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.
    Branco LM; Grove JN; Geske FJ; Boisen ML; Muncy IJ; Magliato SA; Henderson LA; Schoepp RJ; Cashman KA; Hensley LE; Garry RF
    Virol J; 2010 Oct; 7():279. PubMed ID: 20961433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current research for a vaccine against Lassa hemorrhagic fever virus.
    Warner BM; Safronetz D; Stein DR
    Drug Des Devel Ther; 2018; 12():2519-2527. PubMed ID: 30147299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced vaccine candidates for Lassa fever.
    Lukashevich IS
    Viruses; 2012 Oct; 4(11):2514-57. PubMed ID: 23202493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The search for animal models for Lassa fever vaccine development.
    Lukashevich IS
    Expert Rev Vaccines; 2013 Jan; 12(1):71-86. PubMed ID: 23256740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region.
    Cai Y; Iwasaki M; Motooka D; Liu DX; Yu S; Cooper K; Hart R; Adams R; Burdette T; Postnikova EN; Kurtz J; St Claire M; Ye C; Kuhn JH; Martínez-Sobrido L; de la Torre JC
    mBio; 2020 Mar; 11(2):. PubMed ID: 32209677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine platforms for the prevention of Lassa fever.
    Purushotham J; Lambe T; Gilbert SC
    Immunol Lett; 2019 Nov; 215():1-11. PubMed ID: 31026485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.
    Leblanc P; Moise L; Luza C; Chantaralawan K; Lezeau L; Yuan J; Field M; Richer D; Boyle C; Martin WD; Fishman JB; Berg EA; Baker D; Zeigler B; Mais DE; Taylor W; Coleman R; Warren HS; Gelfand JA; De Groot AS; Brauns T; Poznansky MC
    Hum Vaccin Immunother; 2014; 10(10):3022-38. PubMed ID: 25483693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine platforms to control Lassa fever.
    Lukashevich IS; Pushko P
    Expert Rev Vaccines; 2016 Sep; 15(9):1135-50. PubMed ID: 27136941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.
    Bredenbeek PJ; Molenkamp R; Spaan WJ; Deubel V; Marianneau P; Salvato MS; Moshkoff D; Zapata J; Tikhonov I; Patterson J; Carrion R; Ticer A; Brasky K; Lukashevich IS
    Virology; 2006 Feb; 345(2):299-304. PubMed ID: 16412488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses.
    Marzi A; Feldmann F; Geisbert TW; Feldmann H; Safronetz D
    Emerg Infect Dis; 2015 Feb; 21(2):305-7. PubMed ID: 25625358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a new vaccine for the prevention of Lassa fever.
    Geisbert TW; Jones S; Fritz EA; Shurtleff AC; Geisbert JB; Liebscher R; Grolla A; Ströher U; Fernando L; Daddario KM; Guttieri MC; Mothé BR; Larsen T; Hensley LE; Jahrling PB; Feldmann H
    PLoS Med; 2005 Jun; 2(6):e183. PubMed ID: 15971954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins.
    Wang M; Jokinen J; Tretyakova I; Pushko P; Lukashevich IS
    Vaccine; 2018 Jan; 36(5):683-690. PubMed ID: 29287681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of guinea pigs for assessing the efficacy of vaccines against Lassa fever].
    Firsova IV; Shatokhina IV; Borisevich IV; Evseev AA; Maksimov VA; Pantiukhov VB; Khmelev AL
    Vopr Virusol; 2003; 48(6):43-5. PubMed ID: 14708232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity.
    Zapata JC; Poonia B; Bryant J; Davis H; Ateh E; George L; Crasta O; Zhang Y; Slezak T; Jaing C; Pauza CD; Goicochea M; Moshkoff D; Lukashevich IS; Salvato MS
    Virol J; 2013 Feb; 10():52. PubMed ID: 23402317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lassa Virus Countermeasures.
    Melnik LI
    Curr Top Microbiol Immunol; 2023; 440():111-145. PubMed ID: 36253593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection From Lethal Lassa Disease Can Be Achieved Both Before and After Virus Exposure by Administration of Single-Cycle Replicating Lassa Virus Replicon Particles.
    Kainulainen MH; Spengler JR; Welch SR; Coleman-McCray JD; Harmon JR; Scholte FEM; Goldsmith CS; Nichol ST; Albariño CG; Spiropoulou CF
    J Infect Dis; 2019 Sep; 220(8):1281-1289. PubMed ID: 31152662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lassa fever diagnostics: past, present, and future.
    Happi AN; Happi CT; Schoepp RJ
    Curr Opin Virol; 2019 Aug; 37():132-138. PubMed ID: 31518896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.